Biogen Inc. - Dec 28, 2021 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
10%+ Owner
Signature
BIOGEN INC. By: /s/ Michael Dambach, Vice President and Treasurer
Stock symbol
SGMO
Transactions as of
Dec 28, 2021
Transactions value $
-$23,522
Form type
4
Date filed
12/30/2021, 04:12 PM
Previous filing
Dec 28, 2021
Next filing
Aug 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Sale -$23.5K -2.76K -0.01% $8.51* 24.2M Dec 28, 2021 By Biogen MA Inc. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.53, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.